Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21203057 | 0.76 | HTT (0.41) | POLBHSP90AA1ESR2TDP1KDM4E | |
| SCHEMBL29809461 | 0.76 | HTT (0.41) | POLBHSP90AA1ESR2TDP1KDM4E | |
| SCHEMBL8264538 | 0.74 | HSP90AA1 (0.53) | POLBHSP90AA1ESR2TDP1KDM4E | |
| SCHEMBL12431580 | 0.71 | HSP90AA1 (0.69) | POLBHSD17B10HSP90AA1ESR2TDP1 | |
| SCHEMBL7031600 | 0.70 | KDM4E (0.36) | POLBHSD17B10NPSR1HSP90AA1ESR2 | |
| SCHEMBL7029119 | 0.70 | MEN1 (0.43) | POLBHSD17B10NPSR1TDP1KDM4E | |
| SCHEMBL5564735 | 0.69 | KMT2A (0.36) | POLBTDP1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2119014 | 0.68 | KDM4E (0.52) | POLBHSD17B10HSP90AA1TDP1KDM4E | |
| SCHEMBL13907803 | 0.68 | TDP1 (0.53) | POLBHSD17B10NPSR1HSP90AA1ESR2 | |
| SCHEMBL30848233 | 0.67 | HSP90AA1 (0.42) | POLBHSP90AA1ESR2TDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253685-B | Preparation method of tergolian prazan intermediate | 成都安满生物医药科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2024087156-A1 | SCALABLE PRODUCTION METHOD FOR 4-HYDROXY-N,N,2-TRIMETHYLBENZIMIDAZOLE-6-CARBOXAMIDE | 深圳市华先医药科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| WO-2024087155-A1 | METHOD FOR SYNTHESIZING 4-HYDROXY-N,N,2-TRIMETHYLBENZIMIDAZOLE-6-CARBOXAMIDE | 深圳市华先医药科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| WO-2024087157-A1 | METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF TEGOPRAZAN | 深圳市华先医药科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-116178273-B | Method for synthesizing 4-hydroxy-N, N, 2-trimethyl benzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116178273-B | Method for synthesizing 4-hydroxy-N, N, 2-trimethyl benzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116178273-B | Method for synthesizing 4-hydroxy-N, N, 2-trimethyl benzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119100992-A | Preparation method of tergolian intermediate and derivative thereof | 帕潘纳(北京)科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-116253685-B | Preparation method of tergolian prazan intermediate | 成都安满生物医药科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118994026-A | Tegordonin impurity and preparation method and application thereof | 南京桦冠生物技术有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024087157-A1 | METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF TEGOPRAZAN | 深圳市华先医药科技有限公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024087156-A1 | SCALABLE PRODUCTION METHOD FOR 4-HYDROXY-N,N,2-TRIMETHYLBENZIMIDAZOLE-6-CARBOXAMIDE | 深圳市华先医药科技有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-116178273-A | Method for synthesizing 4-hydroxy-N, N, 2-trimethyl benzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115594639-A | Synthesis method of key intermediate of Tegolrazan | 深圳市华先医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115594639-A | Synthesis method of key intermediate of Tegolrazan | 深圳市华先医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115536593-A | Scalable production method of 4-hydroxy-N, N, 2-trimethylbenzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115536593-A | Scalable production method of 4-hydroxy-N, N, 2-trimethylbenzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115536593-A | Scalable production method of 4-hydroxy-N, N, 2-trimethylbenzimidazole-6-formamide | 深圳市华先医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20210251967-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITOR | HK INNO.N CORPORATION (KR) | 2021-08-19 | — | — | US | disclosed |
| WO-2020045940-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITOR | CJ HEALTHCARE CORPORATION (KR) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251967-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITOR | P2RY1, P2RY11, GIPR | POLB 4389/4885HSD17B10 634/4885NPSR1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.